TY - JOUR
T1 - Response assessment in paediatric low-grade glioma
T2 - recommendations from the Response Assessment in Pediatric Neuro-Oncology (RAPNO) working group
AU - Fangusaro, Jason
AU - Witt, Olaf
AU - Hernáiz Driever, Pablo
AU - Bag, Asim K.
AU - de Blank, Peter
AU - Kadom, Nadja
AU - Kilburn, Lindsay
AU - Lober, Robert M.
AU - Robison, Nathan J.
AU - Fisher, Michael J.
AU - Packer, Roger J.
AU - Young Poussaint, Tina
AU - Papusha, Ludmila
AU - Avula, Shivaram
AU - Brandes, Alba A.
AU - Bouffet, Eric
AU - Bowers, Daniel
AU - Artemov, Anton
AU - Chintagumpala, Murali
AU - Zurakowski, David
AU - van den Bent, Martin
AU - Bison, Brigitte
AU - Yeom, Kristen W.
AU - Taal, Walter
AU - Warren, Katherine E.
N1 - Publisher Copyright:
© 2020 Elsevier Ltd
PY - 2020/6
Y1 - 2020/6
N2 - Paediatric low-grade gliomas (also known as pLGG) are the most common type of CNS tumours in children. In general, paediatric low-grade gliomas show clinical and biological features that are distinct from adult low-grade gliomas, and the developing paediatric brain is more susceptible to toxic late effects of the tumour and its treatment. Therefore, response assessment in children requires additional considerations compared with the adult Response Assessment in Neuro-Oncology criteria. There are no standardised response criteria in paediatric clinical trials, which makes it more difficult to compare responses across studies. The Response Assessment in Pediatric Neuro-Oncology working group, consisting of an international panel of paediatric and adult neuro-oncologists, clinicians, radiologists, radiation oncologists, and neurosurgeons, was established to address issues and unique challenges in assessing response in children with CNS tumours. We established a subcommittee to develop consensus recommendations for response assessment in paediatric low-grade gliomas. Final recommendations were based on literature review, current practice, and expert opinion of working group members. Consensus recommendations include imaging response assessments, with additional guidelines for visual functional outcomes in patients with optic pathway tumours. As with previous consensus recommendations, these recommendations will need to be validated in prospective clinical trials.
AB - Paediatric low-grade gliomas (also known as pLGG) are the most common type of CNS tumours in children. In general, paediatric low-grade gliomas show clinical and biological features that are distinct from adult low-grade gliomas, and the developing paediatric brain is more susceptible to toxic late effects of the tumour and its treatment. Therefore, response assessment in children requires additional considerations compared with the adult Response Assessment in Neuro-Oncology criteria. There are no standardised response criteria in paediatric clinical trials, which makes it more difficult to compare responses across studies. The Response Assessment in Pediatric Neuro-Oncology working group, consisting of an international panel of paediatric and adult neuro-oncologists, clinicians, radiologists, radiation oncologists, and neurosurgeons, was established to address issues and unique challenges in assessing response in children with CNS tumours. We established a subcommittee to develop consensus recommendations for response assessment in paediatric low-grade gliomas. Final recommendations were based on literature review, current practice, and expert opinion of working group members. Consensus recommendations include imaging response assessments, with additional guidelines for visual functional outcomes in patients with optic pathway tumours. As with previous consensus recommendations, these recommendations will need to be validated in prospective clinical trials.
UR - http://www.scopus.com/inward/record.url?scp=85085650270&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85085650270&partnerID=8YFLogxK
U2 - 10.1016/S1470-2045(20)30064-4
DO - 10.1016/S1470-2045(20)30064-4
M3 - Review article
C2 - 32502457
AN - SCOPUS:85085650270
SN - 1470-2045
VL - 21
SP - e305-e316
JO - The Lancet Oncology
JF - The Lancet Oncology
IS - 6
ER -